Clinical trials: Cholesterol, LDL
Dyslipidemia
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
The purpose of the study is to assess the effect of AZD0780 on the pharmacokinetics of rosuvastatin, and to assess the safety and tolerability of AZD0780 single dose, in healthy participants administered alone and in combination…
- Trial name
- NCT05787002
- Testing
- AZD0780, Rosuvastatin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypercholesterolemia
Combined Effect of LIMICOL and Physical Activity on LDL Cholesterol and Muscle Function.
Cardiovascular disease (CVD), foremost among which ischemic heart disease and stroke, are the leading cause of mortality and morbidity in France.
- Trial name
- L2012-12 (NCT05750602)
- Testing
- LIMICOL
- Where
- 4 sites in France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lescuyer Laboratory
To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other Comorbidities
Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects
Objectives: The primary and secondary objectives of the study are presented below. Exploratory objectives are presented in the body of the protocol.
- Trial name
- NCT05905068
- Testing
- RN0191 INJECTION
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ikaria Bioscience Pty Ltd
HIV Infections
ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial
This study aims to investigate whether patients switching their backbone from Kivexa to Truvada, who already have raised total cholesterol prior to switching, have an improvement in their total cholesterol after 12 weeks of…
- Trial name
- ROCKET I (NCT00615810)
- Testing
- Atripla, Kivexa plus Sustiva
- Where
- United Kingdom
- Volunteers
- 159 people
- Sponsor
- Gilead Sciences
Hypercholesterolemia, Coronary Heart Disease
Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks
The purpose of this study is to compare the effect of 8 weeks of treatment with Rosuvastatin with 8 weeks of treatment with Atorvastatin on low density lipoprotein cholesterol level in subjects with hypercholesterolemia and…
- Trial name
- POLARIS (NCT00653588)
- Testing
- Rosuvastatin, Atorvastatin
- Sponsor
- AstraZeneca
Primary Hypercholesterolemia, Dyslipidemia
A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
This study is being done to find out if tablets containing extended release (ER) niacin, laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin and laropiprant taken with simvastatin tablets…
- Trial name
- NCT01294683
- Testing
- Simvastatin, Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM), Extended Release (ER) niacin/laropiprant (N/LRPT)
- Volunteers
- 977 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Mixed Dyslipidemia
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in adults with type 2…
- Conditions
- Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
- Trial name
- BANTING (NCT02739984)
- Testing
- Evolocumab
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 424 people
- Sponsor
- Amgen
Diabetes Mellitus Type 2, Crestor, Rosuvastatin
DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines
The purpose of this study is to determine in DM II patients the efficacy of Crestor in obtaining the new European LDL cholesterol guidelines.
- Conditions
- Diabetes Mellitus Type 2, Crestor, Rosuvastatin, LDL Cholesterol, Observational
- Trial name
- NCT00233649
- Where
- 222 sites in Netherlands
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
The study is divided into 2 parts. The first part of the study will be double-blinded and will last for 24 weeks. During this time, participants will be randomized in a ratio of 2:1 to receive either evolocumab once monthly (QM)…
- Trial name
- NCT02833844
- Testing
- Evolocumab
- Where
- 78 sites in United States, Australia and 13 more
- Volunteers
- 467 people
- Sponsor
- Amgen
Hypertriglyceridemia
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 2000 mg/dL.
- Trial name
- MARINE (NCT01047683)
- Testing
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day
- Where
- 60 sites in United States, Denmark and 9 more
- Volunteers
- 229 people
- Sponsor
- Amarin Pharma Inc.
Blood Pressure, Low Density Lipoprotein Cholesterol Level
Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol
The purpose of this study is to evaluate the benefit and tolerability of IQP-AS-118 on the systolic and diastolic blood pressure (BP) and to explore the effects on parameters of lipid metabolism in subjects with elevated BP and…
- Trial name
- NCT02871362
- Testing
- IQP-AS-118
- Where
- Germany
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Hypercholesterolemia, Familial
Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 (mipomersen) as add-on therapy in subjects with Heterozygous Familial Hypercholesterolemia
- Trial name
- NCT00281008
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 44 people
- Sponsor
- Kastle Therapeutics, LLC
Hypercholesterolemia, Coronary Disease
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)
The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.
- Trial name
- NCT00092612
- Testing
- MK0653, ezetimibe
- Volunteers
- 372 people
- Sponsor
- Organon and Co
Familial Hypercholesterolemia - Homozygous
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to <12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein…
- Trial name
- ORION-19 (NCT06597006)
- Testing
- Inclisiran
- Where
- 19 sites in United States, Austria and 9 more
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia
Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)
The purpose of this 6-week study is to compare the reduction in specific levels of cholesterol in patients with high cholesterol.
- Trial name
- NCT00092586
- Testing
- MK0653, ezetimibe, Comparator: statins
- Volunteers
- 2,904 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia
Primary Objective: To evaluate the effect of alirocumab (SAR236553/REGN727) on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo when co-administered with 80 mg of atorvastatin after 8 weeks of treatment in…
- Trial name
- NCT01288469
- Testing
- Alirocumab, Atorvastatin
- Where
- 20 sites in United States
- Volunteers
- 92 people
- Sponsor
- Sanofi
High Levels of Low-density Lipoprotein Cholesterol
Adherence and Persistence to Inclisiran Among Early Users in Germany
The present study was a descriptive, non-interventional, retrospective cohort study aimed at evaluating early data on adherence, persistence, and treatment patterns among patients receiving inclisiran and other lipid-lowering…
- Trial name
- NCT05870657
- Where
- Switzerland
- Volunteers
- 1,109 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Coronary Disease
Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)
This study will evaluate patients who have coronary heart disease to determine if an investigational drug will further lower cholesterol when taken in combination with an approved cholesterol lowering medication.
- Trial name
- NCT00092599
- Testing
- MK0653, ezetimibe
- Volunteers
- 410 people
- Sponsor
- Organon and Co
Cardiovascular Disorder
Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)
Collecting local data, safety and experience trial.
- Trial name
- NCT00652717
- Testing
- Ezetimibe, simvastatin
- Volunteers
- 280 people
- Sponsor
- Organon and Co
Primary Hypercholesterolemia, Mixed Dyslipidemia
Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in home-use using either a pre-filled syringe or autoinjector/pen.
- Trial name
- NCT01849497
- Testing
- Evolocumab Pre-filled Syringe, Evolocumab AI/pen
- Where
- 26 sites in United States, Canada
- Volunteers
- 149 people
- Sponsor
- Amgen